Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
Condition: Herpes Labialis
MeSH terms: Herpes Labialis
Intervention: Acyclovir 5 percent (Perrigo); Acyclovir 5 percent (Reference); Placebo cream
Intervention MeSH terms: Acyclovir
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 4076.0
Sex: All
Minimum age: 12 Years
Healthy volunteers: No

Summary:

      To compare safety and efficacy of Perrigo's antiviral drug product compared to an FDA
      approved antiviral drug product in the treatment of cold sores.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Provides written informed consent/assent

          2. Immunocompetent male or non-pregnant females, >12 years old, with limited,
             non-life-threatening, recurrent herpes simplex labialis.

          3. Subjects must have at least 3 recurrences of herpes simplex labialis per year for the
             past two years.

          4. Females of childbearing potential willing to use an acceptable form of birth control.

          5. Subjects must be in general good health with no clinically significant disease that
             might interfere with the study evaluations in the opinion of the investigator.

          6. Subjects must be willing and able to understand and comply with the requirements of
             the study.

        Exclusion Criteria:

          1. Females who are pregnant or nursing, are not using or does not agree to use an
             acceptable form of contraception during the study, or who intends to become pregnant
             during the study.

          2. The use of antiviral therapies in various forms for a given period of time prior to
             screening and study medication application.

          3. Candidate for or previous use of parenteral antiviral treatment or prophylactic
             antiviral therapy for their recurrent herpes simplex labialis.

          4. Recently received an organ transplant.

          5. Subjects who are immunocompromised, HIV positive or who have any immune-system
             disorders.

          6. Recent major change in immune system status that could seriously affect the clinical
             manifestations of herpes simplex labialis and need for treatment in the opinion of the
             investigator.

          7. Subjects with known or suspected history of a clinically significant systemic disease,
             unstable medical disorders, life-threatening disease or current malignancies.

          8. Subjects with a current episode of herpes simplex labialis that has not completely
             healed.

          9. Presence of any facial skin condition or excessive facial hair that may interfere with
             diagnosis, assessment, and/or healing ability.

         10. History of herpes keratitis.

         11. Subject has a history of hypersensitivity or allergy to any ingredient in the drug
             product.

         12. History of unresponsiveness to topical acyclovir therapy.

         13. Participation in any other clinical study or who have received treatment with any
             investigational drug or device within 30 days prior to screening.

         14. Subjects who have previously enrolled in this study.

         15. Subjects who have received any local medication in the target area during the 2 weeks
             prior to both enrollment/screening and Day 1 (Visit 2).

         16. Subjects who have been treated with immunosuppressive medication therapy within 8
             weeks prior to the study both enrollment/screening and Day 1 (Visit 2).

         17. Subject consumes excessive alcohol, abuses drugs, or has a condition that could
             compromise the subject's ability to comply with study requirements in the
             investigator's opinion.

         18. Use of tanning booths, sun lamps, or excessive exposure to the sun for up to 21 days
             from initiating study medication

         19. Subjects using immunostimulators, dye-light therapy, or psoralen therapy within 30
             days prior to study medication initiation